HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dalle, S. Articles by Bataille, D. Search for Related Content PubMed PubMed Citation Articles by Dalle, S. Articles by Bataille, D. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 16, 10869-10876, April 16, 1999

Miniglucagon (Glucagon 19-29), a Potent and Efficient Inhibitor of Secretagogue-induced Insulin Release through a Ca²⁺ Pathway

Stéphane Dalle, Paul Smith, Philippe Blache, Dung Le-Nguyen, Laurence Le Brigand, François Bergeron, Frances M. Ashcroft, and Dominique Bataille

From INSERM U376, CHU Arnaud-de-Villeneuve, 34295 Montpellier, France and the  University Laboratory of Physiology, Oxford University, Parks Road, Oxford OX1 3PT, United Kingdom

Using the MIN6 B-cell line, we investigated the hypothesis that miniglucagon, the C-terminal (19-29) fragment processed from glucagon and present in pancreatic A cells, modulates insulin release, and we analyzed its cellular mode of action. We show that, at concentrations ranging from 0.01 to 1000 pM, miniglucagon dose-dependently (ID₅₀ = 1 pM) inhibited by 80-100% the insulin release triggered by glucose, glucagon, glucagon-like peptide-1-(7-36) amide (tGLP-1), or glibenclamide, but not that induced by carbachol. Miniglucagon had no significant effects on cellular cAMP levels. The increase in ⁴⁵Ca²⁺ uptake induced by depolarizing agents (glucose or extracellular K⁺), by glucagon, or by the Ca²⁺channel agonist Bay K-8644 was blocked by miniglucagon at the doses active on insulin release. Electrophysiological experiments indicated that miniglucagon induces membrane hyperpolarization, probably by opening potassium channels, which terminated glucose-induced electrical activity. Pretreatment with pertussis toxin abolished the effects of miniglucagon on insulin release. It is concluded that miniglucagon is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca²⁺ channels linked to a pathway involving a pertussis toxin-sensitive G protein.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Costes, C. Broca, G. Bertrand, A.-D. Lajoix, D. Bataille, J. Bockaert, and S. Dalle ERK1/2 Control Phosphorylation and Protein Level of cAMP-Responsive Element-Binding Protein: A Key Role in Glucose-Mediated Pancreatic {beta}-Cell Survival. Diabetes, August 1, 2006; 55(8): 2220 - 2230. [Abstract] [Full Text] [PDF]

				C. Longuet, C. Broca, S. Costes, E. H. Hani, D. Bataille, and S. Dalle Extracellularly Regulated Kinases 1/2 (p44/42 Mitogen-Activated Protein Kinases) Phosphorylate Synapsin I and Regulate Insulin Secretion in the MIN6 {beta}-Cell Line and Islets of Langerhans Endocrinology, February 1, 2005; 146(2): 643 - 654. [Abstract] [Full Text] [PDF]

				G. Fontes, A.-D. Lajoix, F. Bergeron, S. Cadel, A. Prat, T. Foulon, R. Gross, S. Dalle, D. Le-Nguyen, F. Tribillac, et al. Miniglucagon (MG)-Generating Endopeptidase, which Processes Glucagon into MG, Is Composed of N-Arginine Dibasic Convertase and Aminopeptidase B Endocrinology, February 1, 2005; 146(2): 702 - 712. [Abstract] [Full Text] [PDF]

				S. Dalle, C. Longuet, S. Costes, C. Broca, O. Faruque, G. Fontes, E. H. Hani, and D. Bataille Glucagon Promotes cAMP-response Element-binding Protein Phosphorylation via Activation of ERK1/2 in MIN6 Cell Line and Isolated Islets of Langerhans J. Biol. Chem., May 7, 2004; 279(19): 20345 - 20355. [Abstract] [Full Text] [PDF]

				F. Authier, P. H. Cameron, C. Merlen, M. Kouach, and G. Briand Endosomal Proteolysis of Glucagon at Neutral pH Generates the Bioactive Degradation Product Miniglucagon-(19-29) Endocrinology, December 1, 2003; 144(12): 5353 - 5364. [Abstract] [Full Text] [PDF]

				C. F. Deacon, M. Kelstrup, R. Trebbien, L. Klarskov, M. Olesen, and J. J. Holst Differential regional metabolism of glucagon in anesthetized pigs Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E552 - E560. [Abstract] [Full Text] [PDF]

				K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]

				S. Dalle, G. Fontes, A.-D. Lajoix, L. LeBrigand, R. Gross, G. Ribes, M. Dufour, L. Barry, D. LeNguyen, and D. Bataille Miniglucagon (Glucagon 19-29): A Novel Regulator of the Pancreatic Islet Physiology Diabetes, February 1, 2002; 51(2): 406 - 412. [Abstract] [Full Text] [PDF]

				S. A. Hinke, J. A. Pospisilik, H.-U. Demuth, S. Mannhart, K. Kuhn-Wache, T. Hoffmann, E. Nishimura, R. A. Pederson, and C. H. S. McIntosh Dipeptidyl Peptidase IV (DPIV/CD26) Degradation of Glucagon. CHARACTERIZATION OF GLUCAGON DEGRADATION PRODUCTS AND DPIV-RESISTANT ANALOGS J. Biol. Chem., February 11, 2000; 275(6): 3827 - 3834. [Abstract] [Full Text] [PDF]